Vicore Pharma Holding AB (VCRE) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Vicore Pharma Holding AB (VCRE) surged +4.56% to $10.20, trading at 23% of its 52-week range ($7.88 – $17.8). Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.
In parallel, the iDMC conducted its regular safety and benefit-risk review of all available data and raised no concerns. ASPIRE continues as planned and remains on track to report 52-week topline results in mid-2027.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on VCRE today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for VCRE. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Vicore Pharma Holding AB (VCRE) ranks #181 by composite RQD confidence (61/100, grade C-) and #212 by equity capitalization ($2.87B). Within this direct 5-issuer industry benchmark cohort, VCRE leads on earnings valuation at N/A trailing P/E, while IDYA leads on capital efficiency and profitability with -13.8% ROIC and — gross margin. VCRE currently leads its immediate peer cohort in composite quantitative strength at 61/100 (C-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| VCRE
ACTIVE
Vicore Pharma Holding AB | C- | 61/100 | — | — | — | +4.56% | $2.87B | Benchmark Subject |
| VRDN Viridian Therapeutics Inc. | D | 45/100 | — | — | -35.0% | +2.18% | $2.81B | /vrdn-vs-vcre → |
| NRIX Nurix Therapeutics Inc. | D- | 42/100 | — | — | -35.0% | -0.51% | $2.96B | /nrix-vs-vcre → |
| MBX MBX Biosciences Inc. | D | 44/100 | — | — | -26.4% | +0.70% | $2.63B | /mbx-vs-vcre → |
| IDYA IDEAYA Biosciences Inc. | D | 45/100 | — | — | -13.8% | -3.15% | $3.17B | /idya-vs-vcre → |
Vicore Pharma Holding AB (VCRE) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $2.87B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-01, Vicore Pharma Holding AB (NASDAQ: VCRE) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $10.20 (+4.56% 1D, market cap $2.87B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, VCRE ranks #181 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VCRE carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, VRDN (Viridian Therapeutics Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $2.81B) and NRIX (Nurix Therapeutics Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $2.96B). Among the 5-stock peer group, VCRE leads on earnings multiple (N/A) while IDYA leads on capital efficiency (-13.8% ROIC).
For Vicore Pharma Holding AB (VCRE), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #181 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
VCRE last traded at $10.20 (+4.56% on volume of 37,008 shares), positioning the stock +0.49% above its 50-day simple moving average ($10.15) and -7.27% below its 200-day simple moving average ($11.00). Across its 52-week range of $7.88 to $17.80, VCRE sits at the 23.4% percentile with a 14-day RSI of 51.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($8.93 to $11.47).
Why VCRE Stock surged +4.56% Today — RQD Quant Desk Flash. Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.